Needham Downgrades Day One Biopharmaceuticals (DAWN) to Hold
Tweet
Share
E-mailGet Alerts DAWN Hot Sheet
Price: $21.53 --0%
Rating Summary:
3 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 3 | New: 14
Rating Summary:
3 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 3 | New: 14
Join SI Premium – FREE
Needham analyst Ami Fadia downgraded Day One Biopharmaceuticals (NASDAQ: DAWN) from Buy to Hold.
For an analyst ratings summary and ratings history on Day One Biopharmaceuticals click here. For more ratings news on Day One Biopharmaceuticals click here.
Shares of Day One Biopharmaceuticals closed at $12.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Upgrades Silicom Ltd. (SILC) to Buy
- Wolfe Research Upgrades Chevron (CVX) to Outperform (Yesterday)
- H.C. Wainwright Reiterates Buy Rating on MindWalk Holdings (HYFT)
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & Company, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
